Coagulation markers in patients with coronary artery disease
https://doi.org/10.4081/jbr.2022.10259
Accepted: February 22, 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Coronary Artery Disease (CAD) is a major public health problem all over the world, and although diagnostic and treatment approaches are improving, the majority of individuals who suffer CAD will not survive. Therefore, it is a clinical demand to find out new biomarkers for identification of CAD in the earlier stage. The purpose of this study was to determine whether qualitative and quantitative alterations of plasma Soluble Fibrin Monomer Complexes (SFMCs) are associated with cardiovascular events. Additionally, some other well-known biomarkers of hypercoagulation state, such as fibrinogen, and prothrombin were analyzed in plasma of patients with different coronary artery pathologies. We found that plasma SFMC concentrations were remarkably increased in all tested CAD groups. Moreover, the development of CAD was accompanied by the changes in both quantity and quality of SFMC composition compared to that of healthy subjects. Our results also demonstrated the elevated level of high molecular weight Vitamin K-Dependent Protein (VKDP) complexes in plasma of CAD patients, which could be used as a potential biomarker of hypercoagulation state. More studies are clearly needed to investigate whether SFMCs or abnormal forms of VKDPs affect cardiovascular events under CAD development and progression.
Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 2019;234:16812-23. DOI: https://doi.org/10.1002/jcp.28350
Lu L, Liu M, Sun R, et al. Myocardial infarction: symptoms and treatments. Cell Biochem Biophys 2015;72:865-7. DOI: https://doi.org/10.1007/s12013-015-0553-4
Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002;162:2405-10. DOI: https://doi.org/10.1001/archinte.162.21.2405
Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34:719-28. DOI: https://doi.org/10.1093/eurheartj/ehs411
Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.537878
Hung MY, Kounis NG, Lu MY, Hu P. Myocardial ischemic syndromes, heart failure syndromes, electrocardiographic abnormalities, arrhythmic syndromes and angiographic diagnosis of coronary artery spasm: literature review. Int J Med Sci 2020;17:1071-82. DOI: https://doi.org/10.7150/ijms.43472
Rennie JA, Ogston D. Changes in coagulation factors following acute myocardial infarction in man. Haemostasis 1976;5:258-64. DOI: https://doi.org/10.1159/000214141
Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000;20:2489-93. DOI: https://doi.org/10.1161/01.ATV.20.11.2489
Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992;93:651-7. DOI: https://doi.org/10.1016/0002-9343(92)90198-K
Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003;89:601-9. DOI: https://doi.org/10.1055/s-0037-1613566
Lind P, Hedblad B, Stavenow L, et al. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol 2001;21:452-8. DOI: https://doi.org/10.1161/01.ATV.21.3.452
Schneider DJ, Taatjes DJ, Howard DB, Sobel BE. Increased reactivity of platelets induced by fibrinogen independent of ist bindings to the IIb-IIIa surface glycoprotein. A potential contributor to cardiovascular risk. J Am Coll Cardiol 1999;33:261-6. DOI: https://doi.org/10.1016/S0735-1097(98)00515-4
Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68:130-5. DOI: https://doi.org/10.1055/s-0038-1656337
Yoshihisa A, Sato Y, Kimishima Y, et al. Soluble fibrin monomer complex is associated with cardio- and cerebrovascular events in patients with heart failure. Int J Cardiol Heart Vasc 2020;32:100697. DOI: https://doi.org/10.1016/j.ijcha.2020.100697
Sadanaga T, Mitamura H. Soluble fibrin monomer complex levels during oral anticoagulant therapy do not predict subsequent thromboembolic events in patients with permanent atrial fibrillation. Int J Cardiol 2013;168:578-80. DOI: https://doi.org/10.1016/j.ijcard.2013.01.259
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42:1289-1367. DOI: https://doi.org/10.1093/eurheartj/ehaa909
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014;64:1929-49. DOI: https://doi.org/10.1161/CIR.0000000000000095
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-e228.
Kemeny M. A Practical Guide to ELISA. Oxford: Pergamon Press;1991.
Katrii T, Shabanova N, Ostapchuk S, Savchuk O. The characterization of the soluble fibrin monomer complex in patients with acute and one year post acute ischemic stroke. Bulletin of Taras Shevchenko National University of Kyiv: Series “Problems of Physiological Functions Regulation” 2017;1:58-61. DOI: https://doi.org/10.17721/2616_6410.2017.22.58-61
Katrii TB, Vovk TB, Halenova TI, et al. Difference in coagulation markers in acute and one year post acute ischemic stroke. Period Biol 2017;119:189-98. DOI: https://doi.org/10.18054/pb.v119i3.5230
Hosaka A, Miyata T, Aramoto H, et al. Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm. J Vasc Surg 2005; 42:200-5. DOI: https://doi.org/10.1016/j.jvs.2005.03.042
Momot AP, Elykkomov VA, Barkagan ZS. Metodika i klinicheskoe znachenie parakoaguliatsionnogo fenantrolinovogo testa [Methods and clinical significance of paracoagulation phenanthroline test]. Klin Lab Diagn 1996;4:17-20.
Gil M, Zarebiński M, Adamus J. Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina. Int J Cardiol 2002;83:43-6. DOI: https://doi.org/10.1016/S0167-5273(02)00008-6
Ang L, Behnamfar O, Palakodeti S, et al. Elevated baseline serum fibrinogen: effect on 2-year major adverse cardiovascular events following percutaneous coronary intervention. J Am Heart Assoc 2017;6:e006580. DOI: https://doi.org/10.1161/JAHA.117.006580
Ieko M, Naito S, Yoshida M, et al. Plasma soluble fibrin monomer complex as a marker of coronary thrombotic events in patients with acute myocardial infarction. Tohoku J Exp Med 2009; 219:25-31. DOI: https://doi.org/10.1620/tjem.219.25
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
